Literature DB >> 23640217

Validation of 18F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: a stereotactic PET and MRI study.

Koen Mertens1, Marjan Acou, Jel Van Hauwe, Ine De Ruyck, Caroline Van den Broecke, Jean-Pierre Okito Kalala, Yves D'Asseler, Ingeborg Goethals.   

Abstract

AIM: The aim of this study was to validate 18F-FDG PET imaging for differentiating high-grade gliomas (HGGs) from low-grade gliomas (LGGs).
METHODS: Twenty-one patients with gliomas undergoing a stereotactic biopsy underwent PET scanning at conventional and delayed intervals, diagnostic and stereotactic MR examinations. To calculate the uptake at the biopsy site, a 2-mm voxel was selected. Uptake in this voxel was expressed as a percentage of the average uptake per voxel in the normal brain. The difference in uptake between HGG and LGG at conventional and late intervals and the difference in uptake difference between HGG and LGG at both intervals were analyzed using t tests as well as a mixed-model analysis of variance.
RESULTS: At conventional intervals, uptake in LGG was 67% of that in the normal brain. Between early and late intervals, a significant decrease in uptake of 11% (±2.5%) was noted (P = 0.001). Uptake in HGG at conventional intervals was 138% of that in the normal brain. Between early and late intervals, a significant increase in uptake of 43% (±11%) was noted (P = 0.005). The difference in uptake between HGG and LGG was significant both at conventional and delayed intervals (P < 0.001). Moreover, the difference in uptake between both groups was significantly greater (31%) at delayed than at conventional intervals (2%) (P < 0.001).
CONCLUSIONS: The results of this correlative study between tumor grade and 18F-FDG uptake both determined at the stereotactic biopsy site indicate that PET, particularly at delayed intervals, is valid for discriminating LGG from HGG.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23640217     DOI: 10.1097/RLU.0b013e318292a753

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

Review 1.  Dynamic nuclear polarisation: The future of imaging in oncology?

Authors:  Eva M Serrao; Kevin M Brindle
Journal:  Porto Biomed J       Date:  2017-02-10

2.  Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors.

Authors:  Matthias Preuss; Peter Werner; Henryk Barthel; Ulf Nestler; Holger Christiansen; Franz Wolfgang Hirsch; Dominik Fritzsch; Karl-Titus Hoffmann; Matthias K Bernhard; Osama Sabri
Journal:  Childs Nerv Syst       Date:  2014-04-08       Impact factor: 1.475

Review 3.  Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes.

Authors:  Ephraim E Parent; Derek R Johnson; Tyler Gleason; Javier E Villanueva-Meyer
Journal:  Neurooncol Pract       Date:  2021-05-04

Review 4.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959

Review 5.  Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.

Authors:  Vincent Dunet; Anastasia Pomoni; Andreas Hottinger; Marie Nicod-Lalonde; John O Prior
Journal:  Neuro Oncol       Date:  2015-08-04       Impact factor: 12.300

6.  Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Ian Law; Nathalie L Albert; Javier Arbizu; Ronald Boellaard; Alexander Drzezga; Norbert Galldiks; Christian la Fougère; Karl-Josef Langen; Egesta Lopci; Val Lowe; Jonathan McConathy; Harald H Quick; Bernhard Sattler; David M Schuster; Jörg-Christian Tonn; Michael Weller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-05       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.